Table 2.

Crude event rates for CVD death, total mortality, CVD Composite Events, and ESRD for the AASK

Patient SubgroupAll ESRDCVD Composite EventAll Death (Censoring Follow-up at ESRD)CVD Death
Total N (No. of Events; %)Rate/100 patient-yearsTotal N (No. of Events; %)Rate/100 patient-yearsTotal N (No. of Events; %)Rate/100 patient-yearsTotal N (No. of Events; %)Rate/100 patient-years
All patients1094 (318; 29)3.91094 (225; 21)3.21094 (177; 16)2.21094 (59; 5)0.8
Age (years)
    ≤55524 (207; 40)5.4524 (95; 18)2.9524 (52; 10)1.4524 (22; 4)0.6
    >55570 (111; 19)2.6570 (130; 23)3.5570 (125; 22)2.9570 (37; 6)0.9
Baseline UP/Cr
    ≤0.22733 (109; 15)1.8733 (155; 21)3.0733 (123; 17)2.0733 (43; 6)0.8
    >0.22357 (208; 58)10.5357 (69; 19)4.0357 (53; 15)2.7357 (16; 4)0.9
Education
    high school or higher648 (209; 32)4.3648 (115; 18)2.7648 (88; 14)1.8648 (30; 5)0.7
    lower than high school444 (109; 25)3.3444 (110; 25)4.0444 (88; 20)2.7444 (29; 7)1.0
Gender
    female425 (135; 32)4.2425 (82; 19)3.0425 (52; 12)1.6425 (20; 5)0.7
    male669 (183; 27)3.7669 (143; 21)3.4669 (125; 19)2.5669 (39; 6)0.8
Income
    <$15,000521 (152; 29)4.0521 (118; 23)3.7521 (87; 17)2.3521 (29; 6)0.8
    ≥$15,000370 (107; 29)3.8370 (68; 18)2.7370 (56; 15)2.0370 (17; 5)0.6
    declined to answer203 (59; 29)4.0203 (39; 19)3.0203 (34; 17)2.3203 (13; 6)0.9
Mean baseline GFR
    >40718 (106; 15)1.7718 (160; 22)3.1718 (112; 16)1.8718 (41; 6)0.7
    ≤40376 (212; 56)10.2376 (65; 17)3.5376 (65; 17)3.1376 (18; 5)0.9
Preexisting CVD
    yes564 (147; 26)3.5564 (132; 23)3.7564 (105; 19)2.5564 (41; 7)1.1
    no530 (171; 32)4.2530 (93; 18)2.7530 (72; 14)1.8530 (18; 3)0.5
  • Shown are unadjusted incidence rates. Follow-up for CVD events and mortality was terminated at occurrence of ESRD. The follow-up time for ESRD and mortality outcomes included the trial, cohort, and transition periods. The follow-up time for CVD events and CVD deaths included the trial and cohort periods. Similar incidence rates were obtained for each outcome in a sensitivity analysis in which the transition period between the trial and cohort periods was excluded for all events.